New hope for Hard-to-Treat cancers: PTT-4256 enters human trials
NCT ID NCT06634849
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called PTT-4256 in 30 adults with advanced solid tumors that have spread or cannot be removed. The main goal is to check safety and find the best dose. Researchers will also look for early signs that the drug shrinks tumors or slows cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Austin Health
RECRUITINGHeidelberg, Victoria, 3084, Australia
-
Blacktown Hospital
RECRUITINGBlacktown, New South Wales, 2148, Australia
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, 6009, Australia
-
Scientia Clinical Research
RECRUITINGRandwick, New South Wales, 2031, Australia
-
Southern Oncology Clinical Research Unit (SOCRU)
RECRUITINGAdelaide, South Australia, 5042, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?